DTC Act of 2025
- Bill Number
- S. 229
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-01-23: Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337)
- Last Updated
- 2025-12-05T22:02:48Z
Official Summary
Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025
This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law.
Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage.
The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply.
Each violation of this requirement is subject to a civil penalty of not more than $100,000.
Sponsor
Sen. Durbin, Richard J. [D-IL]
Cosponsors (9)
Sen. Grassley, Chuck [R-IA], Sen. King, Angus S., Jr. [I-ME], Sen. Ernst, Joni [R-IA], Sen. Smith, Tina [D-MN], Sen. Welch, Peter [D-VT], Sen. Blumenthal, Richard [D-CT], Sen. Baldwin, Tammy [D-WI], Sen. Tuberville, Tommy [R-AL], Sen. Hyde-Smith, Cindy [R-MS]
Recent Actions
- 2025-01-23: Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337)
- 2025-01-23: Introduced in Senate
Bill Versions
- Drug-price Transparency for Consumers Act of 2025 — issued 2025-01-23 — PDF (11 pages)